InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| Mouse Control IgG2a | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
| 2'3'-cGAMP | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
| STING inhibitor | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
| Recombinant human IFN-γ protein | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
| G3-YSD | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
| Ionomycin | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
| LPS-EB VacciGrade™ | Vitamin A deficiency impairs neutrophil-mediated control of Salmonella via SL... | 2024 | Nat Microbiol. | Lokken-Toyli K.L. et al. | DOI: 10.1038/s41564-024-01613-0 |
| Normocin® - Antimicrobial Reagent | Single-cell and spatial multi-omics highlight effects of anti-integrin therap... | 2024 | Nat Commun. | Mennillo E. et al. | DOI: 10.1038/s41467-024-45665-6 |
| ODN 1826 - TLR9 ligand | Reduction in creatine metabolites in macrophages exposed to small molecule an... | 2024 | Parasite Immunol. | Alanazi S. et al. | DOI: 10.1111/pim.13026 |
| Primocin® | Interplay in galectin expression predicts patient outcomes in a spatially res... | 2024 | Biomed Pharmacother. | Abudu O. et al. | DOI: 10.1016/j.biopha.2024.116283 |
| pFUSE2-CLIg-hK | ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants:... | 2023 | Antib Ther. | Alfaleh M.A. et al. | DOI: 10.1093/abt/tbad030 |
| Anti-hIL-6 Neutralizing mAb | Importance of IL-6 trans-signaling and high autocrine IL-6 production in huma... | 2024 | Osteoarthritis Cartilage | Eitner A. et al. | DOI: 10.1016/j.joca.2024.02.006 |
| Plasmocin® - Mycoplasma Elimination Reagent | Molnupiravir inhibits human norovirus and rotavirus replication in 3D human i... | 2024 | Antiviral Res. | Santos-Ferreira N. et al. | DOI: 10.1016/j.antiviral.2024.105839 |
| Puromycin | Nuclear RNA-related processes modulate the assembly of cytoplasmic RNA granules. | 2024 | Nucleic Acids Res. | Angel M. et al. | DOI: 10.1093/nar/gkae119 |
| Normocin® - Antimicrobial Reagent | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
| IFN-α/β Reporter B16 Cells | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
| IFN-α/β Reporter HEK 293 Cells | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
| QUANTI-Blue™ | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
| Zeocin® | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
| Blasticidin | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |